Sulpiride and breastfeeding by Lasich, A J
September 2005, Vol. 95, No. 9  SAMJ
BRIEWE
Megaloblastic anaemia, diabetes
and deafness in a 2-year-old
child
To the Editor: Megaloblastic anaemic in childhood is usually
caused by dietary folate deficiency or, rarely, congenital
disorders of vitamin B12 or folate metabolism. Thiamine-
responsive megaloblastic anaemia (TRMA) is a rare autosomal-
recessive disorder caused by inactivating mutations of a
thiamine transporter gene.1
We report on a 2-year-old girl referred after 2 episodes of
diabetic ketoacidosis. She was clinically pale and had
sensorineural deafness. Control of her diabetes required 18
units of insulin daily.
Her haemoglobin concentration was 5.4 g/dl, the mean cell
volume 101 fl, and the corrected reticulocyte count 1.4%. There
were oval macrocytes on the blood smear. Red cell folate and
serum vitamin B12 levels were normal. Her bone marrow
aspirate was hypercellular with predominantly erythroid
hyperplasia and trilineage megaloblastic dysplasia. An iron
stain showed numerous ringed sideroblasts (20%).
A provisional diagnosis of TRMA was made and we
administered an intramuscular dose of 100 mg of thiamine,
followed by 50 mg daily by mouth. There was a rapid
reticulocytosis (10.2%) and the haemoglobin concentration
increased to 9.8 g/dl after 14 days. Her daily insulin
requirements fell to 4 units. Unfortunately attempts to
demonstrate apoptosis of fibroblasts in a thiamine-free medium
proved unsuccessful. 
Three years after diagnosis the patient receives 100 mg of
oral thiamine daily, maintains a haemoglobin concentration of
12.2 g/dl and requires only 3 - 5 units of insulin daily. She has
a hearing aid and attends a school for deaf children.
TRMA is the result of mutations of the SLC19A2 gene
(chromosome 1), which codes for a high-affinity thiamine
transporter.2,3 Rapid transport of thiamine by this facilitated
transport system appears to be essential only for
haematopoietic, pancreatic islet and auditory nerve cell
function. Cumulative cell loss via apoptosis explains why the
clinical manifestations are not apparent in early infancy.4
Passive uptake by a separate low-affinity, high-capacity system
appears adequate to protect other tissues from intracellular
thiamine depletion. Hence TRMA patients receiving adequate
dietary thiamine seldom manifest the classic signs of beriberi
(peripheral neuropathy and cardiomyopathy). Thiamine in
pharmacological doses compensates by increasing passive
uptake via the low-affinity system in the affected tissues.
Our patient ran a typical course with a rapid improvement
in the anaemia and a partial response with regard to insulin
requirements on thiamine supplementation, but
characteristically the sensorineural deafness has persisted.1
We suggest that megaloblastic anaemia with normal vitamin
B12 and folate levels should prompt a therapeutic trial of
thiamine, particularly in a deaf and/or diabetic child.
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Sulpiride and breastfeeding
To the Editor: I have been informed by a number of women
that in order to promote the production/flow of breastmilk
their obstetrician-gynaecologist has prescribed sulpiride. The
dosage used is on average 50 mg 3 times a day. The practice of
prescribing sulpiride appears to have become widespread and I
am concerned about the liberal use of a psychotropic agent that
has the potential to affect the newborn infant’s neurobiological
system. 
According to the Maudsley Guidelines all psychotropics pass
into the breastmilk so no decision is risk-free. The Psychotropic
Drug Directory1 states the following: ‘Breast milk is more acidic
than plasma so basic compounds may be retained and
concentrations accumulate. Drug binding to milk protein is less
than to plasma proteins and the higher lipid content of the
‘hind’ milk makes it likely to have a higher drug concentration
than the first half. Milk levels are usually around 1% of
maternal plasma levels, but there have been few formal
studies. Furthermore drugs should be avoided if the infant is
premature (or has renal, hepatic, cardiac or neurological
impairment).’
As sulpiride at low dose acts as a dopaminergic agent it is
likely to have an influence on dopamine release and therefore
receptor synthesis in the newborn. This effect in turn may have
an impact on early neurodevelopment as well as behaviour.
Dopamine as a key neurotransmitter is implicated in a number
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of psychiatric and neurological disorders and one questions the
practice of prescribing an agent such as sulpiride for
breastfeeding mothers.
Research has shown that several processes affecting brain
structure such as myelination of axon fibres, arborisation of
neurons and synaptogenesis occur after birth, and medical
practitioners are therefore duty bound to warn breastfeeding
mothers of the potential risk to the newborn infants when
prescribing a psychotropic agent. 




1. Bazire S. Psychotropic Drug Directory. Salisbury, UK: Fivepin Publishing, 2003/04: 209-216.
2. Stahl SM. Essential Psychopharmacology. 2nd ed. Cambridge: Cambridge University Press,
2002.
High expenses for doctors
To the Editor: I refer to the letter by Dr Ger1 in a recent issue of
the Journal.  Numerous educational studies have shown that
memory retention among health care professionals is poor, and
that practical skills deteriorate within months of training.1
Indeed, as Dr Ger states, ‘Knowledge … is poor after one year
– rewrite or lose your licence to practice’ has been the policy in
many leading international medical institutions for many
years, particularly in the USA.
Although annual recertification in basic and advanced life-
support skills may be optimal, the Resuscitation Council of
Southern Africa has adopted the American Heart Association
policy of recommending renewal in Advanced Cardiovascular
Life Support (ACLS) and Paediatric Advanced Life Support
(PALS) training every 2 years for health care professionals with
a duty to respond to a cardiac or paediatric emergency.
ACLS and PALS courses offered by the Resuscitation Council
of Southern Africa, recognised as being of the highest
international standard and utilising simulators and equipment
costing between 1/4 and 1/2 a million rands, are attended by
doctors, nurses and paramedics from all over South Africa and
worldwide, as they are being offered at a fraction of the price
of similar overseas advanced life-support courses.
We note that Dr Ger would like his SAMA membership fee to
cover the cost of his ‘CPD points, congresses, and revision
courses, plus protection fees’.  Indeed, the acquisition of CPD
points and attendance at congresses and revision courses
would very likely lead to a reduction in medical protection
fees.
W G J Kloeck
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HPCSA – a voice from the other
side
To the Editor: With regard to the letter in your May issue,1 our
CPD Manager Barbara van Staden (who incidentally is a
woman, not a ‘him’ as referred to in the letter) has not received
any enquiries from C D Karabus regarding his CPD points or
any other matter, not have I been requested for a response to
his letter as stated in the Editor’s note below the letter (all
media enquiries are referred to my office).
We are disappointed that the SAMJ has resorted to such
tactics.
Anina Steele
Public Relations and Service Delivery Manager
Health Professions Council of South Africa
Pretoria
1. Karabus CD. HPCSA – the sound of silence. S Afr Med J 2005; 95: 286.   
Professor Karabus replies: After several abortive letters of
request to the HPCSA I thought a letter of complaint to the
SAMJ might be indicated and produce results. It has!
I am now told that Mrs B van Staden is the senior manager
for CPD records and claims never to have received any letters
from me. As my bona fides are called into question may I
provide the following?
1. My 71-point 2002 CPD portfolio (posted to the HPCSA on
12 April 2003, full copy available) was not acknowledged.
2. My e-mail dated 21 January 2004 to Mrs Y Meintjies at the
HPCSA (having been told in error that she was involved with
CPD), together with her very prompt response of 22 January
saying that she had forwarded my request to the CPD
department.
3. My letter dated 24 March 2004 attached to my CPD
portfolio for 2003.
4. My final letter dated 21 May 2004 to the so-called CPD
manager requesting certification.
Copies of all the above have been sent to the Editor of the
Journal.
To put it mildly I am not impressed with the HPCSA.  
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Erratum
In the article entitled ‘The cost of treating serious firearm-
related injuries in South Africa’ by D Allard and V C Burch,
which appeared on pp. 591 - 594 of the August 2005 SAMJ,
there were two errors in the second paragraph of the
discussion. In the first sentence, ‘US$2.9 million’ should have
read ‘US$29 million’, and in the third sentence ‘4% of the total’
should have read ‘1% of the total’.
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